decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.chlorpromazinetrazodone, chlorpromazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.trazodone, chlorpromazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.chlorpropamidetrazodone increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.cisatracuriumcisatracurium and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.conjugated estrogensconjugated estrogens, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.conjugated estrogens, vaginalconjugated estrogens, vaginal, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.cyclizinecyclizine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.cyclobenzaprinecyclobenzaprine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.cyclophosphamidecyclophosphamide will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.darifenacindarifenacin and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.desfluranedesflurane, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.dexmethylphenidatedexmethylphenidate increases effects of trazodone by decreasing metabolism. Minor/Significance Unknown.DHEA, herbalDHEA, herbal will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.dicyclominedicyclomine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.diphenhydraminediphenhydramine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.donepezildonepezil increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.echothiophate iodideechothiophate iodide increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.eletriptantrazodone, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.estradiolestradiol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens conjugated syntheticestrogens conjugated synthetic, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens esterifiedestrogens esterified, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estropipateestropipate, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.ethacrynic acidethacrynic acid, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.ethanolethanol, trazodone. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive impairment of motor skills.ethinylestradiolethinylestradiol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Oxidative metabolism of TCAs may be decreased by ethinyl estradiol. Increased antidepressant serum concentrations may occur. Potential for increased TCA adverse effects.ethotointrazodone increases levels of ethotoin by unspecified interaction mechanism. Minor/Significance Unknown.etomidateetomidate, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.eucalyptustrazodone and eucalyptus both increase sedation. Minor/Significance Unknown.fesoterodinefesoterodine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.fexofenadinetrazodone will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.flavoxateflavoxate and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.fluphenazinetrazodone, fluphenazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.trazodone, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.fosphenytointrazodone increases levels of fosphenytoin by unspecified interaction mechanism. Minor/Significance Unknown.frovatriptantrazodone, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.furosemidefurosemide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.galantaminegalantamine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.glimepiridetrazodone increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.glipizidetrazodone increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.glyburidetrazodone increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.glycopyrrolateglycopyrrolate and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.glycopyrrolate inhaledglycopyrrolate inhaled and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.trazodone increases levels of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown.hydroxyprogesterone caproate (DSC)hydroxyprogesterone caproate (DSC), trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.insulin asparttrazodone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.insulin detemirtrazodone increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.insulin glarginetrazodone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.insulin glulisinetrazodone increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.insulin lisprotrazodone increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.insulin NPHtrazodone increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.insulin regular humantrazodone increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.isoproterenolisoproterenol, trazodone. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.ketamineketamine, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.larotrectiniblarotrectinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.lithiumlithium, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.trazodone, lithium. Mechanism: unknown. Minor/Significance Unknown. Risk of neurotoxicity.loratadinetrazodone will decrease the level or effect of loratadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.lovastatintrazodone increases levels of lovastatin by unspecified interaction mechanism. Minor/Significance Unknown.mestranolmestranol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.metformintrazodone increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.miglitoltrazodone increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.naratriptantrazodone, naratriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.nateglinidetrazodone increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.neostigmineneostigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.onabotulinumtoxinAonabotulinumtoxinA and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.panax ginsengpanax ginseng increases effects of trazodone by pharmacodynamic synergism. Minor/Significance Unknown.pentobarbitalpentobarbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.perphenazinetrazodone, perphenazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.trazodone, perphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.phenobarbitalphenobarbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.phenytointrazodone increases levels of phenytoin by unspecified interaction mechanism. Minor/Significance Unknown.physostigminephysostigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.pilocarpinepilocarpine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.pioglitazonetrazodone increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.pitavastatintrazodone increases levels of pitavastatin by unspecified interaction mechanism. Minor/Significance Unknown.pleurisy rootpleurisy root decreases effects of trazodone by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.pravastatintrazodone increases levels of pravastatin by unspecified interaction mechanism. Minor/Significance Unknown.primidoneprimidone, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.prochlorperazinetrazodone, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.trazodone, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.progesterone micronizedprogesterone micronized, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.promazinetrazodone, promazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.trazodone, promazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.promethazinetrazodone, promethazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.trazodone, promethazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.propofolpropofol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.pyridostigminepyridostigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.repaglinidetrazodone increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.rivastigminerivastigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.rizatriptantrazodone, rizatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.rosiglitazonetrazodone increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.rosuvastatintrazodone increases levels of rosuvastatin by unspecified interaction mechanism. Minor/Significance Unknown.ruxolitinibtrazodone will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ruxolitinib topicaltrazodone will increase the level or effect of ruxolitinib topical by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.sagetrazodone and sage both increase sedation. Minor/Significance Unknown.saxagliptintrazodone increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.secobarbitalsecobarbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.serdexmethylphenidate/dexmethylphenidateserdexmethylphenidate/dexmethylphenidate increases effects of trazodone by decreasing metabolism. Minor/Significance Unknown.sevofluranesevoflurane, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.simvastatintrazodone increases levels of simvastatin by unspecified interaction mechanism. Minor/Significance Unknown.sitagliptintrazodone increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.succinylcholinesuccinylcholine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.sulfamethoxazolesulfamethoxazole decreases levels of trazodone by unspecified interaction mechanism. Minor/Significance Unknown.sumatriptantrazodone, sumatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.sumatriptan intranasaltrazodone, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.thioridazinetrazodone, thioridazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.trazodone, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.tolazamidetrazodone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.tolbutamidetrazodone increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.torsemidetorsemide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.trifluoperazinetrazodone, trifluoperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.trazodone, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.vasopressintrazodone increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.verapamilverapamil increases levels of trazodone by decreasing metabolism. Minor/Significance Unknown.vildagliptintrazodone increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.zafirlukastzafirlukast will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.zolmitriptantrazodone, zolmitriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.zolpidemzolpidem, trazodone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.5-HTPMonitor Closely (1)trazodone and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.abametapirSerious - Use Alternative (1)abametapir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.acarboseMinor (1)trazodone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.aceclofenacMonitor Closely (1)trazodone, aceclofenac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.acemetacinMonitor Closely (1)trazodone, acemetacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.acetazolamideMinor (1)acetazolamide will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.aclidiniumMonitor Closely (1)aclidinium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.acrivastineMonitor Closely (1)acrivastine and trazodone both increase sedation. Use Caution/Monitor.albuterolMonitor Closely (2)trazodone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. albuterol and trazodone both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)trazodone, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.alfentanilMonitor Closely (1)alfentanil and trazodone both increase sedation. Use Caution/Monitor.aliskirenMonitor Closely (1)trazodone will decrease the level or effect of aliskiren by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.almotriptanMonitor Closely (1)almotriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (1)trazodone, almotriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.alprazolamMonitor Closely (1)alprazolam and trazodone both increase sedation. Use Caution/Monitor.alvimopanMinor (1)trazodone will decrease the level or effect of alvimopan by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.amikacinMonitor Closely (1)trazodone will decrease the level or effect of amikacin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.amiodaroneSerious - Use Alternative (1)trazodone and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.amisulprideMonitor Closely (1)amisulpride and trazodone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trazodone and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.amitriptylineMonitor Closely (3)trazodone will decrease the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. amitriptyline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor. amitriptyline and trazodone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)amitriptyline and trazodone both increase QTc interval. Avoid or Use Alternate Drug. trazodone and amitriptyline both increase serotonin levels. Avoid or Use Alternate Drug.amobarbitalMonitor Closely